animal viral hepatitis: A hepatitis that involves viral infection of an animal causing inflammation of the liver.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
97 |
4. Check minimum number of eventsNone |
97 |
5. Include endpointsNone |
97 |
6. Filter based on genotype QC (FinnGen only) |
94 |
Control definitions (FinnGen only)
- Control exclude
- IBD_CMV
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cytomegaloviral hepatitis
based on the number of shared cases.
Similar with more cases:
- Cytomegalovirus infection, IBD co-morbidity
- Cytomegaloviral disease
- Infections, IBD-co-morbidities
- Other viral diseases
- Other viral diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 572 | 309 | 258 |
| Only index persons | 496 | 268 | 228 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 39.29 | 44.09 | 33.25 |
| Only index persons | 38.68 | 43.17 | 33.39 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 94 | 60 | 34 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 44.05 | 46.57 | 39.60 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 97
- Matched controls
- 970
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K77.0*B25.1
ICD-10 Finland
Cytomegaloviral hepatitis
+∞
66.5
56
*
B25.1
ICD-10 Finland
Cytomegaloviral hepatitis
+∞
23.9
22
*
0785B
ICD-9 Finland
Other diseases due to viruses and Chlamydiae, Cytomegaloviral disease[HEPATITIS CYTOMEGALICA]
+∞
20.5
19
*
R50.9
ICD-10 Finland
Fever, unspecified
7.3
20.4
42
92
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.7
12.1
27
61
K75.9
ICD-10 Finland
Inflammatory liver disease, unspecified
26.9
12.0
16
7
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
6.0
11.7
24
50
A05AA02
ATC
ursodeoxycholic acid; oral
32.3
11.1
14
5
127
Kela drug reimbursment
Transplant complication
26.9
10.6
14
6
L04AA06
ATC
mycophenolic acid; systemic
26.9
10.6
14
6
Z94.4
ICD-10 Finland
Liver transplant status
110.3
9.6
10
*
K76.9
ICD-10 Finland
Liver disease, unspecified
98.2
8.6
9
*
L04AD02
ATC
tacrolimus; systemic
98.2
8.6
9
*
L04AX01
ATC
azathioprine; systemic
11.5
7.8
14
14
TK800
NOMESCO Finland
Hemodialysis
27.5
7.7
10
*
JJC00
NOMESCO Finland
Allogenic transplantation of liver
+∞
7.4
7
*
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
+∞
7.4
7
*
K83.0
ICD-10 Finland
Cholangitis
32.7
7.3
9
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
15.3
7.1
11
8
H02AB04
ATC
methylprednisolone; systemic
3.7
6.7
26
88
L04AD01
ATC
ciclosporin; systemic
12.2
6.5
11
10
K73.2
ICD-10 Finland
Chronic active hepatitis, not elsewhere classified
+∞
6.3
6
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.9
6.3
15
25
JN4AD
NOMESCO Finland
Body CT examination
4.5
6.3
17
44
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
23
14
21.07
15.72
1.0
1.1
476.50
142.78
u/ml
—
8
9
23
15
19.65
15.35
1.0
1.3
—
—
—
0
0
22
56
4.79
8.43
6.2
2.5
6.03
5.84
kpa
0.42
22
56
12
9
14.99
7.61
1.1
1.1
—
—
—
0
0
52
260
3.16
7.22
6.0
2.9
—
—
—
0
0
44
203
3.14
6.97
5.1
2.7
0.13
0.39
e6/l
1.29
35
149
30
112
3.43
6.70
5.7
2.7
2.76
3.20
e6/l
0.09
18
64
61
356
2.92
6.09
13.3
6.5
1.21
1.22
mmol/l
0.63
53
303
30
121
3.14
5.84
5.6
2.5
0.44
0.98
e6/l
1.38
18
71
13
20
7.32
5.78
1.5
1.3
—
—
—
0
0
9
7
13.99
5.70
1.1
1.0
—
—
—
0
0
24
88
3.30
5.43
2.0
1.9
—
—
—
0
0
15
33
5.18
5.13
7.7
2.2
24.07
24.79
mmol/l
0.34
15
33
16
47
3.88
5.00
3.8
2.4
5.08
4.70
kpa
0.24
16
47
29
126
2.86
4.88
2.0
2.0
—
—
—
0
0
22
85
3.05
4.52
1.8
1.8
—
—
—
0
0
7
6
12.43
4.34
1.4
1.5
—
—
—
0
0
24
100
2.86
4.31
5.3
2.0
23.37
21.49
%
0.26
19
86
11
21
5.76
4.29
2.5
2.0
94.55
91.62
%
0.10
11
21
9
13
7.50
4.27
1.8
2.1
—
—
—
0
0
14
36
4.37
4.20
1.6
1.2
—
—
—
0
0
53
338
2.25
3.75
19.2
11.5
1.01
1.16
inr
2.02
12
102
13
36
4.01
3.66
2.1
1.8
—
—
—
0
0
33
180
2.26
3.33
2.4
2.1
—
—
—
0
0
6
7
9.03
3.31
3.2
1.6
0.95
0.87
g/l
—
6
7
53
354
2.10
3.17
4.2
2.4
109.59
97.92
ug/l
0.23
48
327
8
16
5.34
3.12
3.6
2.8
5.19
6.66
u/ml
—
8
16
15
58
2.88
3.04
2.6
2.1
55.60
77.20
ml/min/173m2
—
5
25
15
60
2.77
2.86
13.6
2.8
107.27
66.45
ng/l
0.82
15
53
9
23
4.20
2.85
1.4
1.4
—
—
—
0
0
55
385
1.99
2.77
10.1
4.8
0.00
0.00
estimate
-0.00
12
76
55
390
1.95
2.62
7.3
3.6
0.00
0.00
estimate
-0.00
11
73
7
19
3.88
2.19
1.3
2.1
—
—
—
0
0
92
829
3.13
2.10
30.7
12.9
19.81
21.95
mg/l
0.30
82
625
8
26
3.26
2.06
1.4
1.1
—
—
—
0
0
16
79
2.23
1.99
2.3
3.3
—
—
—
0
0
52
385
1.76
1.97
7.6
3.5
0.00
0.00
estimate
-0.00
13
83
5
11
4.73
1.96
1.0
1.1
—
—
—
0
0
9
34
2.81
1.92
2.7
4.1
23.41
25.39
mmol/l
—
9
34
7
22
3.35
1.92
1.7
2.3
0.00
0.00
g/l
—
7
22
7
22
3.35
1.92
1.7
2.3
0.00
0.00
g/l
—
7
22
8
28
3.02
1.91
1.8
2.1
3.70
3.83
g/l
—
8
28
8
28
3.02
1.91
1.8
2.1
6.76
7.85
g/l
—
8
28
8
28
3.02
1.91
1.8
2.1
—
—
—
0
0
5
12
4.33
1.84
1.0
1.0
—
—
—
0
0
16
83
2.11
1.77
3.1
2.3
34.12
28.70
u/l
0.44
16
66
7
24
3.06
1.76
1.7
2.2
35.53
38.70
g/l
—
7
24
7
24
3.06
1.76
1.7
2.3
0.00
0.00
g/l
—
7
24
7
24
3.06
1.76
1.7
2.3
0.00
0.65
g/l
—
7
24
12
55
2.35
1.76
5.1
4.7
1.24
1.23
mmol/l
0.23
12
50
15
76
2.15
1.75
2.1
1.9
361.60
389.80
nmol/l
0.19
15
70
27
171
1.80
1.70
2.0
1.7
1.12
0.83
mg/l
0.24
20
139
7
25
2.94
1.68
1.6
2.0
—
—
—
0
0
8
32
2.63
1.64
4.0
1.3
0.23
0.24
g/l
—
8
32
27
173
1.78
1.63
2.4
1.9
2.80
2.79
mg/l
0.01
22
153
7
26
2.82
1.61
1.7
2.2
3.43
3.02
g/l
—
7
26
8
33
2.55
1.57
4.0
1.6
—
—
—
0
0
8
33
2.55
1.57
4.0
1.3
1.14
1.21
g/l
—
8
33
7
28
2.61
1.48
3.0
2.7
25.87
25.47
mmol/l
—
7
28
49
377
1.61
1.47
2.8
2.4
—
—
—
0
0
69
579
1.66
1.44
3.7
3.2
—
—
—
0
0
6
23
2.71
1.39
2.7
1.2
—
—
—
0
0
9
43
2.20
1.34
3.0
1.3
—
—
—
0
0
10
49
2.16
1.27
3.2
1.6
—
—
—
0
0
22
144
1.68
1.22
1.6
1.5
—
—
—
0
0
27
197
1.51
0.96
6.7
4.0
0.00
0.00
estimate
-0.00
12
75
5
102
0.46
0.96
1.6
1.7
—
—
—
0
0
6
27
2.30
0.95
3.7
3.1
56.80
55.35
%
—
6
27
6
28
2.22
0.93
1.3
2.5
0.78
1.01
%
—
6
28
25
185
1.47
0.83
1.5
1.5
—
—
—
0
0
37
299
1.38
0.76
1.8
2.0
111.40
97.66
pmol/l
0.80
24
146
5
26
1.97
0.71
2.4
1.3
—
—
—
0
0
5
26
1.97
0.71
1.6
1.5
—
—
—
0
0
5
26
1.97
0.71
2.4
1.3
—
—
—
0
0
5
27
1.90
0.69
1.6
1.2
—
—
—
0
0
12
78
1.61
0.69
6.2
6.2
104.33
103.56
mmol/l
0.20
12
78
7
43
1.68
0.68
4.0
1.8
—
—
—
0
0
29
230
1.37
0.66
1.9
1.7
1.32
1.37
mmol/l
0.14
29
196
0
20
0.00
0.61
0.0
1.7
—
—
—
0
0
36
300
1.32
0.59
7.6
3.6
—
—
—
0
0
18
134
1.42
0.58
1.6
1.6
1526.15
1194.67
nmol/l
0.45
13
99
83
779
1.45
0.58
24.8
11.9
78.73
85.70
ml/min/173m2
1.48
74
630
5
32
1.59
0.43
2.0
2.4
—
—
—
0
0
79
754
1.26
0.32
4.9
5.0
37.01
39.38
mmol/mol
2.89
72
716
7
51
1.40
0.32
4.1
2.0
—
—
—
0
0
23
199
1.20
0.27
6.8
3.8
15.57
6.91
mg/mmol
0.62
14
117
8
101
0.77
0.22
1.8
1.8
—
—
—
0
0
8
100
0.78
0.22
6.3
4.4
33.25
32.55
%
—
8
64
0
11
0.00
0.21
0.0
5.0
—
107.43
—
0
11
0
10
0.00
0.21
0.0
1.0
—
482.20
—
0
5
0
10
0.00
0.21
0.0
1.0
—
35.20
—
0
5
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
19
168
1.16
0.17
1.4
1.3
22.12
29.48
iu/ml
—
9
63
60
625
0.90
0.16
4.0
4.2
14.80
14.70
pmol/l
0.12
55
569
13
146
0.87
0.11
5.2
3.8
25.88
22.38
%
—
7
67
10
112
0.88
0.07
1.8
2.0
—
—
—
0
0
8
91
0.87
0.07
2.5
4.4
5.05
56.42
ug/l
—
8
74
74
751
0.94
0.05
4.4
4.8
1.72
1.85
mu/l
0.53
69
685
28
288
0.96
0.02
4.2
3.5
34.32
35.14
ng/l
0.01
22
179
20
196
1.03
0.00
1.5
1.2
0.62
0.71
u/ml
—
6
54
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
9
94
0.95
-0.00
24.9
6.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
0.30
—
0
6
0
6
0.00
-0.00
0.0
2.5
—
125.17
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CMV_HEPATITIS and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have CMV_HEPATITIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: CMV_HEPATITIS – Cytomegaloviral hepatitis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data